Development of Membrane-Bound GM-CSF and IL-18 as an Effective Tumor Vaccine.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 26186692.
- Also identified by DOI 10.1371/journal.pone.0133470 and PMC identifier 4506079.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
The development of effective adjuvant is the key factor to boost the immunogenicity of tumor cells as a tumor vaccine. In this study, we expressed membrane-bound granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-18 (IL-18) as adjuvants in tumor cells to stimulate immune response. B7 transmembrane domain fused GM-CSF and IL-18 was successfully expressed in the cell membrane and stimulated mouse splenocyte proliferation. Co-expression of GM-CSF and IL-18 reduced tumorigenesis (P<0.05) and enhanced tumor protective efficacy (P<0.05) significantly in comparison with GM-CSF alone. These results indicated that the combination of GM-CSF andIL-18 will enhance the immunogenicity of a cell-based anti-tumor vaccine. This membrane-bound approach can be applied to other cytokines for the development of novel vaccine strategies.
Medical subject headings
- Cancer Vaccines
- Carcinogenesis
- Granulocyte-Macrophage Colony-Stimulating Factor
- Interleukin-18